Personalis provides cancer genomic testing services for physicians, drug developers, and diagnostics companies. It last closed at $14.80 on Nov 17, up 0.00% on the day. In the past 30 days there were 1 dark pool print totaling $792K, the largest $792K.
PSNL · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, oversold
The stock is 6% below its 20 day and 8% below its 50 day average. It is 21% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 28), oversold. The nearest support is the Pivot at $14.78, and the nearest resistance the swing high (Aug 10) at $14.81.
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityLow, 2.3%/day
Key levels
$18.8952 week high+27.6%
$15.9950 day average+8.0%
$15.7420 day average+6.4%
$15.30100 day average+3.4%
$15.04Pivot R1+1.6%
$14.81Swing high (Aug 10)+0.1%
$14.80Last close
$14.78Pivot−0.1%
$14.54Pivot S1−1.8%
$13.68Swing low (Aug 18)−7.6%
$11.63200 day average−21.4%
$4.9652 week low−66.5%
Indicators
RSI (14)
27.75
Oversold below 30
Oversold
MACD
-0.19
Below its signal line
Bearish
Stochastic
16.9
Near the bottom of its range
Oversold
ADX (14)
20.5
Weak trend
Williams %R
-81.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-358.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−6.0%
Change over 10 sessions
Bearish
ATR (14)
$0.35
Typical daily range, 2.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumNeutral
StretchNormal
VolatilityLow, 8.7%/day
Key levels
$18.8952 week high+27.6%
$15.9950 day average+8.0%
$15.7420 day average+6.4%
$15.30100 day average+3.4%
$15.04Pivot R1+1.6%
$14.81Swing high (Aug 10)+0.1%
$14.80Last close
$14.78Pivot−0.1%
$14.54Pivot S1−1.8%
$13.68Swing low (Aug 18)−7.6%
$11.63200 day average−21.4%
$4.9652 week low−66.5%
Indicators
RSI (14)
53.75
Middle of its range
Neutral
MACD
1.29
Below its signal line
Bearish
Stochastic
37.7
Middle of its range
Neutral
ADX (14)
40.5
Strong uptrend
Williams %R
-78.5
Oversold below −80, overbought above −20
Neutral
CCI (20)
-27.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−8.7%
Change over 10 sessions
Bearish
ATR (14)
$1.29
Typical daily range, 8.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for PSNL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PSNL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PSNL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PSNL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PSNL is in one of them and how their past PSNL trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Personalis
Personalis is a cancer genomics company based in Fremont, California. It offers genomic testing that helps physicians detect residual or recurring cancer, track how a tumor responds to treatment, and select therapies. It also sells testing to pharmaceutical and biotech companies for clinical trials and biomarker research, and provides sequencing services to diagnostics companies and population sequencing projects. Its customers include drugmakers, diagnostics firms, universities, government bodies, and cancer patients.